2021 EHRA实践指南《非维生素K拮抗剂口服抗凝药物在房颤患者中的应用指南》更新解读

2021-12-01 医药导报

该指南就NOACs在心房颤动患者应用的16 种场景提出实用指导。该文通过与2018 版“指南”进行对比，对更新内容进行详细解读，以期为临床应用抗凝药物提供参考。

中文标题：

发布机构：

发布日期：

2021-12-01

简要介绍：

2021年4月，欧洲心律协会（EHRA）发布2021 版《非维生素K拮抗剂口服抗凝药物在房颤患者中的应用指南》（简称“指南”），指出非维生素Ｋ拮抗剂口服抗凝药物（NOACs）是房颤患者预防卒中的首选抗凝药，该指南就NOACs在心房颤动患者应用的16 种场景提出实用指导。该文通过与2018 版“指南”进行对比，对更新内容进行详细解读，以期为临床应用抗凝药物提供参考。

点击查看指南原文：2021 EHRA实践指南：非维生素拮抗剂口服抗凝药物在房颤患者中的应用

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=8764d1c002282afb, title=2021 EHRA实践指南《非维生素K拮抗剂口服抗凝药物在房颤患者中的应用指南》更新解读, enTitle=, guiderFrom=医药导报, authorId=0, author=, summary=该指南就NOACs在心房颤动患者应用的16 种场景提出实用指导。该文通过与2018 版“指南”进行对比，对更新内容进行详细解读，以期为临床应用抗凝药物提供参考。, cover=https://img.medsci.cn/2021123/1638521793202_1608702.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Wed Dec 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=2021年4月，欧洲心律协会（EHRA）发布2021 版《非维生素K拮抗剂口服抗凝药物在房颤患者中的应用指南》（简称“指南”），指出非维生素Ｋ拮抗剂口服抗凝药物（NOACs）是房颤患者预防卒中的首选抗凝药，该指南就NOACs在心房颤动患者应用的16 种场景提出实用指导。该文通过与2018 版“指南”进行对比，对更新内容进行详细解读，以期为临床应用抗凝药物提供参考。 点击查看指南原文：<a href="//m.sandwebs.com/guideline/show_article.do?id=46a061c00209956e">2021 EHRA实践指南：非维生素拮抗剂口服抗凝药物在房颤患者中的应用</a>, tagList=[TagDto(tagId=318, tagName=心律失常), TagDto(tagId=364, tagName=房颤), TagDto(tagId=118958, tagName=非维生素K拮抗剂口服抗凝药物)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=113832, guiderKeyword=非维生素K拮抗剂口服抗凝剂, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3336, appHits=269, showAppHits=0, pcHits=872, showPcHits=3065, likes=1, shares=46, comments=9, approvalStatus=1, publishedTime=Fri Dec 03 17:37:11 CST 2021, publishedTimeString=2021-12-01, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Fri Dec 03 17:03:57 CST 2021, updatedBy=6459136, updatedName=艺玮, updatedTime=Fri Jan 05 13:39:32 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 EHRA实践指南《非维生素K拮抗剂口服抗凝药物在房颤患者中的应用指南》更新解读.pdf)])

2021 EHRA实践指南《非维生素K拮抗剂口服抗凝药物在房颤患者中的应用指南》更新解读.pdf

下载请点击：

评论区 (9)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1205231, encodeId=90c712052315d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Wed Mar 23 15:11:11 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180226, encodeId=6bd911802268b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=379a6445098, createdName=ms4000000479270390, createdTime=Mon Jan 03 23:34:33 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084058, encodeId=5915108405852, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Fri Dec 24 21:49:25 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083329, encodeId=9f6210833295f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:53:30 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083328, encodeId=d29110833288c, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:53:22 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
2022-03-23 17326332

学习

90 0
[GetPortalCommentsPageByObjectIdResponse(id=1205231, encodeId=90c712052315d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Wed Mar 23 15:11:11 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180226, encodeId=6bd911802268b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=379a6445098, createdName=ms4000000479270390, createdTime=Mon Jan 03 23:34:33 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084058, encodeId=5915108405852, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Fri Dec 24 21:49:25 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083329, encodeId=9f6210833295f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:53:30 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083328, encodeId=d29110833288c, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:53:22 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
2022-01-03 ms4000000479270390

学习了

100 0
[GetPortalCommentsPageByObjectIdResponse(id=1205231, encodeId=90c712052315d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Wed Mar 23 15:11:11 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180226, encodeId=6bd911802268b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=379a6445098, createdName=ms4000000479270390, createdTime=Mon Jan 03 23:34:33 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084058, encodeId=5915108405852, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Fri Dec 24 21:49:25 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083329, encodeId=9f6210833295f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:53:30 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083328, encodeId=d29110833288c, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:53:22 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
2021-12-24 坚定的心

学习了

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1205231, encodeId=90c712052315d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Wed Mar 23 15:11:11 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180226, encodeId=6bd911802268b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=379a6445098, createdName=ms4000000479270390, createdTime=Mon Jan 03 23:34:33 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084058, encodeId=5915108405852, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Fri Dec 24 21:49:25 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083329, encodeId=9f6210833295f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:53:30 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083328, encodeId=d29110833288c, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:53:22 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
2021-12-22 一己怀

谢谢分享

115 0
[GetPortalCommentsPageByObjectIdResponse(id=1205231, encodeId=90c712052315d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Wed Mar 23 15:11:11 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180226, encodeId=6bd911802268b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=379a6445098, createdName=ms4000000479270390, createdTime=Mon Jan 03 23:34:33 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084058, encodeId=5915108405852, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Fri Dec 24 21:49:25 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083329, encodeId=9f6210833295f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:53:30 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083328, encodeId=d29110833288c, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:53:22 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
2021-12-22 一己怀

谢谢分享

91 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

2021 EHRA实践指南《非维生素K拮抗剂口服抗凝药物在房颤患者中的应用指南》更新解读

相关指南

科室

工具

服务